GlobalData, the industry analysis specialist, has released its new report, “Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics – Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Chemotherapy induced Nausea and Vomiting Therapeutics market. The report identifies the key trends shaping and driving the global Chemotherapy induced Nausea and Vomiting Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Chemotherapy induced Nausea and Vomiting Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Chemotherapy induced Nausea and Vomiting Therapeutics market. Its scope includes –
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Chemotherapy induced Nausea and Vomiting Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Chemotherapy induced Nausea and Vomiting Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Chemotherapy induced Nausea and Vomiting Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Chemotherapy induced Nausea and Vomiting Therapeutics market
Chemotherapy-Induced Nausea and Vomiting Therapeutics Market
Published: February 2012
No.OF Pages: 81
Price: Single User License US$ 3995 Corporate User License US$ 11985
Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics – Introduction 7
2.1 Overview 7
2.1.1 Classification of Chemotherapy-Induced Nausea and Vomiting 7
2.2 Risk factors for Chemotherapy-Induced Nausea and Vomiting 8
2.3 Epidemiology 10
2.4 Symptoms 10
2.5 Etiology 10
2.6 Pathophysiology 11
2.7 Diagnosis 13
2.8 Treatment of Chemotherapy-Induced Nausea and Vomiting 13
2.8.1 Current Guidelines 13
2.8.2 Prevention of CINV by Emetogenic Potential of Chemotherapy and Class 20
2.9 GlobalData Pipeline Report Guidance 22
3 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics – Market Characterization 23
3.1 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) – Global 23
3.2 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) – Global 25
3.3 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) – the US 27
3.4 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) – the US 28
3.5 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) – France 29
3.6 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) – France 30
3.7 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) – Germany 31
3.8 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) – Germany 32
3.9 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) – Italy 33
3.10 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) – Italy 34
3.11 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) – Spain 35
3.12 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) – Spain 36
3.13 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) – the UK 37
3.14 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) – the UK 38
3.15 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) – Japan 39
3.16 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) – Japan 40
3.17 Drivers and Barriers for the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market 41
3.17.1 Drivers for the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market 41
3.17.2 Barriers for the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market 41
3.18 Key Events Impacting the Future Market 42
3.19 Opportunity and Unmet Need Analysis 42
3.19.1 Key Takeaway 43
4 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics – Competitive Assessment 44
4.1 Overview 44
4.2 Strategic Competitor Assessment 44
4.3 Product Profile for the Major Marketed Products in the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market 45
4.3.1 Anzemet (dolasetron mesylate) 45
4.3.2 Kytril (granisetron) 46
4.3.3 Sancuso (granisetron Transdermal System) 47
4.3.4 Zuplenz/Zofran (ondansetron) 48
4.3.5 Aloxi (palonosetron hydrochloride) 49
4.3.6 Emend (aprepitant/fosaprepitant dimeglumine) 50
4.4 Key Takeaway 52
5 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics – Pipeline Assessment 53
5.1 Overview 53
5.2 Strategic Pipeline Assessment 53
5.3 Chemotherapy-Induced Nausea and Vomiting Pipeline – Pipeline by Phases of Development 53
5.3.1 Chemotherapy-Induced Nausea and Vomiting Therapeutics – Pre-registration Pipeline 54
5.3.2 Chemotherapy-Induced Nausea and Vomiting Therapeutics – Phase III Pipeline 54
5.3.3 Chemotherapy-Induced Nausea and Vomiting Therapeutics – Phase II Pipeline 54
5.3.4 Chemotherapy-Induced Nausea and Vomiting Therapeutics – Phase I Pipeline 54
5.3.5 Chemotherapy-Induced Nausea and Vomiting Therapeutics – Preclinical 55
5.3.6 Chemotherapy-Induced Nausea and Vomiting Therapeutics – Discovery 55
5.4 Chemotherapy-Induced Nausea and Vomiting Therapeutics – Pipeline by Mechanism of Action 55
5.5 Chemotherapy-Induced Nausea and Vomiting Technology Trends Analytical Framework 56
5.6 Molecule Profile for Key Late Stage Drugs under Clinical Development 57
5.6.1 APF530 57
5.6.2 EUR-1025 58
5.6.3 Netupitant 58
5.7 Key takeaway 58
6 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics – Clinical Trials Mapping 59
6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 59
6.2 Clinical Trials Mapping by Phase 60
6.3 Clinical Trials Mapping by Trial Status 61
6.4 Overall Sponsors 62
6.5 Prominent Sponsors 63
6.6 Top Companies Participating in Chemotherapy-Induced Nausea and Vomiting Therapeutics Clinical Trials 64
7 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics – Strategic Assessment 65
7.1 Chemotherapy-Induced Nausea and Vomiting Therapeutics – Implications for Future Market Competition 65
8 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics – Future Players 66
8.1 Introduction 66
8.2 Company Profiles 66
8.2.1 A.P. Pharma Inc. 66
8.2.2 Aptalis Pharma, Inc. 68
8.2.3 Eisai Co. Ltd 69
8.2.4 Helsinn Healthcare S.A. 71
9 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics – Licensing and Partnership Deals 72
10 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics – Appendix 74
10.1 Definitions 74
10.2 Acronyms 74
10.3 Research Methodology 75
10.3.1 Coverage 75
10.3.2 Secondary Research 76
10.3.3 Forecasting 76
10.3.4 Primary Research 78
10.3.5 Expert Panel Validation 79
10.4 Contact Us 79
10.5 Disclaimer 79
10.6 Bibliography 79
List of Tables
List of Figures